Entity

Time filter

Source Type


Karn P.R.,Yonsei Institute of Pharmaceutical science | Do Kim H.,Yonsei Institute of Pharmaceutical science | Do Kim H.,Yonsei University | Kang H.,Yonsei Institute of Pharmaceutical science | And 6 more authors.
International Journal of Nanomedicine | Year: 2014

Background: The objective of this study was to compare the efficacy of cyclosporin (CsA)-encapsulated liposomes with the commercially available CsA emulsion (Restasis®) for the treatment of dry eye syndrome in rabbits. Methods: Liposomes containing CsA were prepared by the supercritical fluid (SCF) method consisted of phosphatidylcholine from soybean (SCF-S100) and egg lecithins (SCF-EPCS). An in vitro permeation study was carried out using artificial cellulose membrane in Franz diffusion cells. Dry eye syndrome was induced in male albino rabbits and further subdivided into untreated, Restasis®-treated, EPCS, and S100-treated groups. Tear formation in the dry-eyeinduced rabbits was evaluated using the Schirmer tear test. All formulations were also evaluated by ocular irritation tests using the Draize eye and winking methods with the determination of CsA concentration in rabbit tears. Results: After the treatment, the Schirmer tear test value significantly improved in EPCS-treated (P=0.005) and S100-treated (P=0.018) groups compared to the Restasis®-treated group. The AUC0-24 h for rabbit's tear film after the administration of SCF-S100 was 32.75±9.21 μg{dot operator}h/mg which was significantly higher than that of 24.59±8.69 μg{dot operator}h/mg reported with Restasis®. Liposomal CsA formulations used in this study showed lower irritation in rabbit eyes compared with Restasis®. Conclusion: These results demonstrate that the novel SCF-mediated liposomal CsA promises a significant improvement in overcoming the challenges associated with the treatment of dry eyes. © 2014 Karn et al. Source

Discover hidden collaborations